⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20382 | 1.00 | — | — | |
| SCHEMBL487540 | 1.00 | — | — | |
| SCHEMBL2398839 | 0.70 | — | — | |
| SCHEMBL4663512 | 0.69 | — | — | |
| SCHEMBL121523 | 0.69 | — | — | |
| SCHEMBL834126 | 0.69 | — | — | |
| SCHEMBL115384 | 0.69 | — | — | |
| SCHEMBL10903965 | 0.67 | — | — | |
| SCHEMBL16763463 | 0.67 | — | — | |
| SCHEMBL10903964 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012467-B2 | Small molecule DCN1 inhibitors and therapeutic methods using the same | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-18 | — | — | US | disclosed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| CN-110740996-B | Covalent small molecule DCN1 inhibitors and methods of treatment using the same | 密执安大学评议会 | 2024-01-09 | — | — | CN | disclosed |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-09 | — | — | US | disclosed |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-02 | — | — | US | disclosed |
| CN-113840885-B | Antifouling coating composition | 日东化成株式会社 | 2022-11-15 | — | — | CN | disclosed |
| EP-3609876-B1 | COVALENT SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| US-20220024899-A1 | BI-FUNCTIONAL NANOHYBRIDS | SON (FR) | 2022-01-27 | — | — | US | disclosed |
| CN-113840885-A | Antifouling coating composition | 日东化成株式会社 | 2021-12-24 | — | — | CN | disclosed |
| EP-2132200-B1 | NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS | THRESHOLD PHARMACEUTICALS INC (US) | 2016-03-23 | — | — | EP | disclosed |
| US-7977361-B2 | Nitro-imidazole hypoxia imaging agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7807394-B2 | Nitro-imidazole hypoxia imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7592383-B2 | thermoconductive blends of end capped polysiloxanes, alumina fillers surface treated with end capped polysiloxanes, having plasticity and moldability | DOW CORNING TORAY COMPANY, LTD. (JP) | 2009-09-22 | — | — | US | disclosed |
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-08 | — | — | US | disclosed |
| EP-1558679-B1 | HEAT CONDUCTIVE SILICONE COMPOSITION | DOW CORNING TORAY CO LTD (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20060100336-A1 | thermoconductive blends of end capped polysiloxanes, alumina fillers surface treated with end capped polysiloxanes, having plasticity and moldability | DOW TORAY CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| EP-1558679-A1 | HEAT CONDUCTIVE SILICONE COMPOSITION | Dow Corning Toray Silicone Company, Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004041938-A1 | HEAT CONDUCTIVE SILICONE COMPOSITION | DOW CORNING TORAY SILICONE CO., LTD. (JP) | 2004-05-21 | — | — | WO | disclosed |